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Original Article
Magnesium induces preconditioning
of the neonatal brain via profound
mitochondrial protection
Gabriella Koning1, Anna-Lena Leverin1, Syam Nair1,
Leslie Schwendimann2, Joakim Ek1, Ylva Carlsson3,
Pierre Gressens2,4, Claire Thornton4, Xiaoyang Wang1,
Carina Mallard1 and Henrik Hagberg1,3,4
Abstract
Magnesium sulphate (MgSO4) given to women in preterm labor reduces cerebral palsy in their offspring but the mech-
anism behind this protection is unclear, limiting its effective, safe clinical implementation. Previous studies suggest that
MgSO4 is not neuroprotective if administered during or after the insult, so we hypothesised that MgSO4 induces
preconditioning in the immature brain. Therefore, we administered MgSO4 at various time-points before/after unilateral
hypoxia-ischemia (HI) in seven-day-old rats. We found that MgSO4 treatment administered as a bolus between 6 days and
12 h prior to HI markedly reduced the brain injury, with maximal protection achieved by 1.1mg/g MgSO4 administered
24 h before HI. As serum magnesium levels returned to baseline before the induction of HI, we ascribed this reduction in
brain injury to preconditioning. Cerebral blood flow was unaffected, but mRNAs/miRNAs involved in mitochondrial
function and metabolism were modulated by MgSO4. Metabolomic analysis (H
þ-NMR) disclosed that MgSO4 attenuated
HI-induced increases in succinate and prevented depletion of high-energy phosphates. MgSO4 pretreatment preserved
mitochondrial respiration, reducing ROS production and inflammation after HI. Therefore, we propose that MgSO4
evokes preconditioning via induction of mitochondrial resistance and attenuation of inflammation.
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Introduction
Perinatal brain injury in term and preterm infants
remains a paramount clinical problem causing death
and neurological disabilities.1,2 Approximately 30% of
infants born preterm (<28 gestational weeks) will suﬀer
from cerebral palsy (CP), cognitive impairment or
neuropsychiatric disorders.3–5 CP is the most common
cause of severe disability in children (2/1000 births) and
a major cost to suﬀerers, their families and society,6,7
underscoring the need for development of treatment
and preventive strategies.
Magnesium administered as magnesium sulphate
(MgSO4) has neuroprotective properties. Clinical
cohort studies demonstrated that oﬀspring of mothers
treated with antenatal MgSO4 (given to inhibit preterm
labor or as seizure prophylaxis in preeclampsia) had
a lower risk of developing CP8 and intraventricular/
periventricular hemorrhage.9 Randomized controlled
trials have subsequently conﬁrmed these results10–12
and a meta-analysis showed that the rate of CP or
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moderate/severe motor disability is reduced 30% by
antenatal MgSO4.
13 Additionally, recent discoveries
demonstrate that the rates of echolucent/echodense
brain lesions,14 as well as cerebellar hemorrhages,15
were attenuated. However, the mechanisms behind
this protective eﬀect remain obscure and the optimal
dose for neuroprotection in preterm fetuses/neonates
without serious side eﬀects is unknown.
Preconditioning is a phenomenon whereby sub-
threshold exposure or chemical agents confer resistance
to a subsequent severe insult.16 The immature brain is
responsive to a number of preconditioning exposures,
e.g. sub-threshold hypoxia17,18 or pre-exposure to
pharmacological agents such as xenon19 which reduce
hypoxic-ischemic (HI) brain injury substantially.
Clinically, MgSO4 is given antenatally to mothers in
preterm labor well in advance of the expected critical
period for development of brain injury. Indeed, the
issue of timing is critical as there is no evidence of eﬃ-
cacy when MgSO4 is administered immediately before,
during or after the insult.20–22 Here we investigate our
hypothesis that MgSO4 induces preconditioning,
thereby providing tolerance to insults such as HI or
excitotoxicity occurring during the early neonatal
period, and deﬁne the mechanisms underlying its neu-
roprotective eﬀect. A better understanding of the mech-
anisms behind the neuroprotective actions of MgSO4
will optimize the eﬃcacy and safety of treatment in
preterms and widen its potential therapeutic applica-
tions in high-risk pregnancies to prevent asphyxial
brain injury or prior to open heart surgery in neonates.
Materials and methods
Experimental design
Prior to data acquisition, a power analysis was per-
formed for calculation of appropriate sample size for
reliable measurements. Final endpoints/rules for stop-
ping data collection were set in advance and all experi-
ments, including potential outliers, were included. Pups
were randomly allocated to diﬀerent groups from a var-
iety of litters to avoid litter-speciﬁc outcome and
marked numerically rather than according to individual
treatment. During analysis, samples for microtubule-
associated protein-2 (MAP-2) and myelin basic protein
(MBP), analyzed for serum Mg2þ content, proton
nuclear magnetic resonance (Hþ-NMR), mRNA/
miRNA, mitochondrial respiration, reactive oxygen
species (ROS) formation, Bio Plex and cerebral blood
ﬂow (CBF) measurements were completely blinded to
the researchers through numerical sample-marking
with the researchers unaware of group belonging in
order to avoid bias. Male and female Wistar rat pups
from in house breeding at the facility of Experimental
Biomedicine (EBM) were used along with Swiss mice
from the Robert Debre hospital rodent facility. Animal
experimental procedures conformed to guidelines
established by the Swedish Board of Agriculture
(SJVFS 2015: 38), were approved by the Gothenburg
Animal Ethics Committee (ethical license 333-2012,
138-2013 and 01-2016) or by the Bichat-Robert Debre
committee (ethical license 2011-14/646-048) and are
reported in a manner consistent with the ARRIVE
(Animal Research: Reporting in Vivo Experiments)
guidelines. Animals were housed at EBM or at the
Robert Debre hospital with access to food and water
ad libitum. Mortality was low and not diﬀerent
between groups.
Preconditioning
Wistar rats were randomized into two groups and
injected intraperitoneally (i.p.) with an MgSO4 bolus
(Magnesium sulphate, 1 mmol/ml, Addex; Fresenius
Kabi, Halden, Norway) (1.1mg/g (n¼ 245), 0.55mg/g
(n¼ 46) or 0.37mg/g (n¼ 41)) or as vehicle an equiva-
lent volume of saline (Saline 9mg/ml, B Braun
Melsungen AG, Melsungen, Germany) prior to the
induction of HI. The optimal dose (1.1mg/g) was
injected at diﬀerent time-points prior to (six days
(n¼ 43), 72 h (n¼ 36), 24 h (n¼ 41), 12 h (n¼ 33), 3 h
(n¼ 35) and 30min (n¼ 33)) or post (1 h (n¼ 31) HI.
Brain injury was evaluated by macroscopic scoring and
immunohistochemical staining seven days after HI.
Hypoxia-ischemia
At PND 7, pups were exposed to HI as previously
described.23,24 Rats were anesthetized (isoﬂurane 1.5–
5%) (IsoFlo vet 100%; Abbott Laboratories Ltd,
Illinois, USA) in 1:1 oxygen-nitrogen mixture. The
left common carotid artery was ligated with a 6.0 silk
suture (Seide; Vo¨mel, Germany), the incision closed
and inﬁltrated with a local anesthetic (Xylocain
20mg/ml, lidocain, hydrochloride; Astra Zeneca,
So¨derta¨lje, Sweden). The total duration was <5min.
Pups were returned to their dams for recovery (1 h),
then placed in a humidiﬁed chamber with air for
10min, followed by 60min hypoxia (8% oxygen in
nitrogen), and 10min in air (36C).
Tissue collection and processing
On PND 14, rats were deeply anesthetized (0.1ml of
thiopental, Pentocur, Thiopental, 50mg/ml i.p.; Abcur
AB, Helsingborg, Sweden) and killed for histological
processing; brains were ﬁxed by transcardial perfu-
sion (6% paraformaldehyde, Histoﬁx; Histolab,
Gothenburg, Sweden). Once dissected out, brains
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were photographed and graded macroscopically
according to a previously published protocol25 (Table
S1). After dehydration, brains were paraﬃn-embedded
and cut (Meditome A550) into 7 mm thick sections at
3.3mm from bregma.26
Immunohistochemistry
Sections were prepared for immunohistochemical stain-
ing by deparaﬃnation in xylene followed by graded
alcohol rehydration and boiling in 0.01M citric acid
buﬀer (pH6.0) for antigen recovery followed by block-
ing of endogenous peroxidase/nonspeciﬁc binding (3%
H2O2). Sections were incubated overnight with primary
antibody: Mouse anti-MAP-2 (1:1000; M4403 Sigma-
Aldrich, St. Louis, Missouri, USA) or Mouse anti-
MBP (1:10,000; SMI-94 Covance, Princeton, New
Jersey, USA), washed and incubated in appropriate sec-
ondary antibody. ABC elite was used for visualization
of immunoreactivity followed by submersion into
0.5mg/ml 3.3-diaminobenzidine, NiSO4.
Brain injury evaluation
Brain injury was quantiﬁed as area loss of MAP-2
immunoreactivity at the level of anterior hippocampus.
Total MAP-2 positive area was measured in each hemi-
sphere (MicroImage, 4.0, Olympus Optical) and tissue
loss calculated as MAP-2 positive area in the ipsilateral
hemisphere subtracted from the contralateral. Loss of
MBP was used immunohistochemically to determine
white matter injury. The MBP positive staining was
measured (MicroImage, 4.0, Olympus Optical) in
both hemispheres and the proportion of white matter
injury was calculated by comparing the ipsilateral hemi-
sphere to the contralateral.
Serum Mg2þ measurement
Pups (PND 6) were injected i.p. with MgSO4, (1.1mg/g
(n¼ 17), 0.55mg/g (n¼ 13), 0.37mg/g (n¼ 14)) or vehi-
cle (n¼ 18) and decapitated after 3 or 24 h followed by
immediate blood-collection. Serum was stored (80C)
until analysis for Mg2þ-content (Cobas 8000 Roche
Diagnostics Scandinavia AB) by Centrallaboratoriet
Klinisk Kemi, Sahlgrenska University Hospital,
Gothenburg, Sweden.
RNA preparation
Pups (PND 6) were injected with MgSO4 (1.1mg/g) or
vehicle and deeply anesthetized (0.1ml of thiopental,
sodium pentotal, 50mg/ml i.p.) after 3 or 24 h (n¼ 6/
group), perfused with saline (0.9% Sodium Chloride
Solution) and brains collected, snap-frozen and stored
in 80C. Total RNA including miRNA was prepared
from whole cortex samples using miRNeasy Mini Kit
(Qiagen). The RNA quality, (RQI-scores) was 9–10 as
checked with Experion RNA STDsense chip (Biorad).
Purity and amount were determined using Nano Drop
(260/280 ratio of 1.9 - 2.1).
GeneChip expression analysis
Array expression analysis was performed according to
the Aﬀymetrix expression analysis technical manual,
Genomics Centre, King’s College London. Brieﬂy,
double-stranded cDNA was synthesized from total
RNA and an in vitro transcription reaction was per-
formed to produce biotin-labeled cRNA which was
fragmented and hybridized to Aﬀy mRNA array
Gene ST v2.0, APT v1.15 (36,685 genes) and Aﬀy
miRNA 4.0. CEL ﬁles using the robust multi-array
average algorithm27 performing three distinct oper-
ations: global background normalization, across array
normalization, and log2 transformation of perfect
match values (http://stat-www.berkeley.edu/users/bol-
stad/RMAExpress/RMAExpress.html). The robust
multi-array average analysis, data management, statis-
tical analysis, and gene ontology was performed using
GeneSifter (http://login.genesifter.net/) and IPA
(https://analysis.ingenuity.com).
RT-PCR
cDNA was prepared from 1 mg RNA using QuantiTect
Reverse Transcription Kit (Qiagen). Each PCR (20lL)
((2 lL cDNA, 10 lL Quanti Fast SYBR Green
PCR Master Mix (Qiagen) and 2 lL PCR primer
(QuantiTech Primer Assay, Qiagen)), was run on a
LightCycler 480 (Roche, Sweden) (Table S2). Melting
curve analysis ensured that only one PCR product was
obtained and a standard curve generated using increas-
ing concentrations of cDNA ensured quantiﬁcation/
estimation ampliﬁcation eﬃciency. Ampliﬁed tran-
scripts were quantiﬁed using the relative standard
curve and normalized against the reference
gene Ywhaz. Results were expressed as Cq; the
diﬀerence in the quantiﬁcation cycle (Cq) values
between the target and reference genes.28 The diﬀerence
in Cq for the diﬀerent samples was then directly
compared.
Mitochondrial isolation
Pups (PND 6) were injected with MgSO4 (1.1mg/g)
(n¼ 34) or vehicle (n¼ 37) and decapitated after 24 h
(with or without HI). One hemisphere was immediately
excised and homogenized in 3.8ml 12% Percoll (GE
Healthcare, Bio-Sciences AB, Uppsala, Sweden) in
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ice-cold MIB [225mM mannitol, 75mM sucrose, 1mM
EGTA, 5mM HEPES–KOH, pH7.2, 1mg/mL fatty-
acid-free bovine serum albumin (BSA)] using a
Dounce Homogenizer (7ml, #432-1271, VWR).
Homogenate was pipetted onto 3.5ml 26% Percoll
laying on 3.5ml 40% Percoll in centrifuge tubes, sub-
sequently centrifuged at 30,000g for 10min (4C). The
mitochondrial fraction was moved to a 2ml tube con-
taining 1500 ml MIB (ratio 1:4) and centrifuged at
15,000g for 5min (4C). Pellets were washed in 1ml
MIB, centrifuged at 15,000g for 5min (4C) and resus-
pended in 75 ml MIB containing BSA 1mg/ml.
High-resolution respirometry and O2k-fluorometry
The Oxygraph-2k (O2k, OROBOROS Instruments,
Innsbruck, Austria) was used for measurements of res-
piration and combined with the Fluorescence-Sensor
Green, O2k-Fluo LED2-Module for H2O2 measure-
ment. A protocol modiﬁed from our published meth-
ods29 was used for mitochondrial respiration
measurements in the O2k. Measurements were per-
formed on mitochondria (25C) in 2.1mL MIR05 res-
piration buﬀer [20mM HEPES, 10mM KH2PO4,
110mM sucrose, 20mM taurine, 60mM K-lactobio-
nate, 0.5mM EGTA, 3mM MgCl26H2O, 1 g/L BSA
(fatty acid free)]. Pyruvate and malate (5mM and
2.5mM, respectively) or succinate (10mM) with or
without 0.5mM Complex-I inhibitor rotenone (Rot)
were used to determine Complex-I (CI) or Complex-
II-(CII) linked LEAK respiration. ADP (f.c.
0.14mM) was added which was saturating for oxygen
ﬂux to obtain oxidative phosphorylation (OXPHOS)
capacity. FCCP (1mM) was added to determine elec-
tron transfer system (ETS) capacity. Respiratory con-
trol ratio (RCR) was calculated as the ratio of the
STATE 3 (ADP stimulated respiration of isolated
coupled mitochondria in the presence of high ADP
and Pi concentrations) to the resting respiration rate
STATE 4 (respiratory state obtained in isolated mito-
chondria when ADP has been maximally phosphory-
lated to ATP).
Mitochondrial ROS formation can be detected with
an H2O2 sensitive probe, here Amplex
 UltraRed was
used and a CII-linked protocol measuring respiration
and H2O2 ﬂux simultaneously in the O2k-Fluorometer
was applied. For further details see O2k-Fluorometry in
Supplementary Materials.
For ROS production measurements, mitochondria
were stimulated with ADP followed by rotenone,
blocking Complex-I mediated respiration, allowing
for the study of ROS produced solely at Complex-II
driven by succinate addition. To induce maximal res-
piration/ROS production, FCCP (1 mM) was added.
Volume-speciﬁc H2O2 ﬂuxes were calculated real-time
(DatLab software, OROBOROS INSTRUMENTS,
Innsbruck Austria). The stable portions of the H2O2
ﬂuxes were selected and artifacts induced by addition
of substrates/chemicals were excluded. Values were
normalized to total protein content.30–32
Metabolomics
Brains were collected at 3 h (n¼ 10) or 24 h (n¼ 10)
following injection (PND 6) with MgSO4 (1.1mg/g)
or vehicle (n¼ 18); 24 h after injection with MgSO4
(1.1mg/g) (n¼ 9) or vehicle (n¼ 10), pups were exposed
to HI (60min) and brains collected immediately after
hypoxia. Animals were decapitated and whole heads
snap-frozen in 80C isopenthane. Portions (10–
30mg) of parietal cortex were dissected out (20C)
and solubilized in 3 mol/L HClO4
33 (10C). After cen-
trifugation at 5000g for 10min, one volume of the
supernatant was neutralized with 2.5 volumes of
KHCO3 (2 mol/L) and centrifuged to remove precipi-
tated KHCO3. Blood was collected at decapitation and
serum prepared as described above and saved in 2ml
Micro tubes (Sarstedt Aktiengesellshaft & Co,
D-51588Nu¨mbrecht) (80C). For detailed description
of Hþ-NMR protocol see Metabolomics in
Supplementary Materials.
CBF
CBF was measured using the iodoantipyrine method34
adapted for the immature rat.35,36 The measurements
were performed in both hemispheres 24 h after MgSO4
or vehicle administration without exposure to HI (no
HI; vehicle n¼ 11, MgSO4 n¼ 9), after 30min of HI
(30min HI; vehicle n¼7, MgSO4 n¼ 8) and after
60min of HI (60min HI; vehicle n¼ 9, MgSO4 n¼ 8).
In all animals, 10 mCi, 100 ml 4-Iodo(N-metyl14C) anti-
pyrine (ARC 0126A, ARC; USA) was subcutaneously
injected in the neck followed by decapitation after 60 s.
Blood, 10 ml, was collected directly and the hemispheres
were dissected out, dissolved in SolvebleTM (Perkin
Elmer, Massachusetts; USA) and mixed with Ultima
Gold TM (Perkin Elmer, Massachusetts; USA).
Samples were measured in a Beta-counter, Tricarb
3810tr (Perkin Elmer, Massachusetts, USA) and calcu-
lated as previously described.37
BioPlex
Pups were exposed to HI 24 h after MgSO4 injection
(1.1mg/g) (n¼ 20) or vehicle (n¼ 20). Brains were col-
lected at 6 or 24 h following hypoxia, sonicated in PBS-
buﬀer (5mM EDTA, 1% Triton X-100, 1% Protease
Inhibitor Cocktail (P8340, Sigma)) and centrifuged at
10,000g for 10min (4C). Supernatants were diluted in
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Sample Diluent (Bio-Plex kit, Bio-Rad) and run on a
Bio-Plex ProTM Rat Cytokine 24-plex Assay
(#171K1001MSP, Bio-Rad) according to the manufac-
turer’s instruction.
Statistical measurements
All statistical analyses (except for gene expression and
metabolomic analysis described above) were performed
using Graph Pad Prism. Statistical signiﬁcance was
determined by nonparametric unpaired Mann–
Whitney U-test, paired or unpaired two-tailed
t-tests or ANOVA with or without Tukey’s multiple
comparisons test as speciﬁed in each ﬁgure legend
(MeanSEM). P values< 0.05 were considered
statistically signiﬁcant. The number of sampled units,
n, is stated for each experiment in the methodologic
section.
Results
MgSO4 pre-treatment reduces the extent of neonatal
brain injury after HI
The eﬀect of MgSO4 on neonatal brain injury was ﬁrst
explored in a well-established model of HI in seven-
day-old rats.23 Macroscopic brain injury scoring
(Table S1) showed that rats pre-treated with MgSO4
(1.1mg/g) 24 h prior to HI had markedly reduced
brain damage 0.47 0.14 (n¼ 16) compared with
2.30 0.18 (n¼ 18) in pups pre-treated with saline
(p< 0.0001) (Figure 1(a) and (c)). Signiﬁcant protec-
tion, was also seen when MgSO4 was administered six
days prior to HI ( 0.9 0.2 (n¼ 21) in MgSO4-treated
pups vs. 1.9 0.3 (n¼ 20) in controls (p< 0.005)), three
days prior to HI (1.7 0.2 (n¼ 18) in MgSO4-treated
pups compared with 2.3 0.2 (n¼ 18) in controls
(p< 0.05)) and 12 h prior to HI: 1.1 0.2 (n¼ 17) in
MgSO4-treated pups vs. 2.3 0.1 (n¼ 16) in controls
(p< 0.0001). The overall eﬀect of MgSO4 (1.1mg/g) 6
days–12 h prior to HI is summarized in Figure 1(b)
(n¼ 72/group). MgSO4 had no signiﬁcant eﬀect on
brain injury when administered 3 h or 30min prior to
or 1 h after HI (Figure 1(c)). We also assessed the eﬀect
of MgSO4 pre-treatment on the loss of grey matter
using immunoreactivity for MAP-2 and found a signiﬁ-
cant reduction in tissue loss when MgSO4 was given
72 h prior to HI (39.8 4.6% (n¼ 17) vs. 57.5 4.3%
(n¼ 18) in controls (p¼ 0.01)), 24 h prior to HI
(18.3 4.4% (n¼ 15) in MgSO4-treated pups compared
with 46.1 4.8% (n¼ 19) in controls (p¼ 0.0003)) and
at 12 h prior to HI (48.9 3.7% (n¼ 18) in MgSO4-
treated pups vs. 60.3 3.2% (n¼ 17) in controls
(p¼ 0.03); Figure 1(a) and(c)). For assessment of
white matter loss, we estimated MBP immunoreactivity
and found signiﬁcant diﬀerences in the groups
pre-treated with MgSO4 at 72 h prior to HI: loss of
MBP positive immunoreactivity was 53.8 9.2%
(n¼ 18) in MgSO4-treated pups and 78.0 5.3%
(n¼ 18) in controls (p¼ 0.03). This was maintained in
treatments at 24 h prior to HI (15.0 8.4% (n¼ 15) in
MgSO4-treated pups vs. 70.4 7.4% (n¼ 19) in con-
trols (p< 0.0001)) and 12 h prior to HI (34.8 9.3%
(n¼ 18) in MgSO4-treated pups compared with
84.3 3.8% (n¼ 17) in controls (p¼ 0.03); Figure 1(a)
and (c)).
There are exposures other than HI that are believed
to elicit preterm brain injury so we evaluated the neu-
roprotective eﬀect of MgSO4 in a well-characterized
excitotoxic model of preterm brain injury.38 MgSO4
(0.92mg/g) 24 h prior to ibotenate injection (10mg)
reduced both grey and white matter injury
(Figure S1) supporting the concept that MgSO4 oﬀers
eﬃcacy in the treatment of immature brain injury
regardless of its aetiology.
The neuroprotective dose of MgSO4
induces preconditioning
As the optimal interval between MgSO4 treatment and
HI was 24 h, the next step was to identify the optimal
dose required for maximal protection. We injected
PND 6 rats with diﬀerent doses of MgSO4 (0.37mg/g,
0.55mg/g or 1.1mg/g) 24 h prior to HI. Brains were
analyzed as described above and we found that only a
dose of 1.1mg/g provided the animals with signiﬁcant
protection (Figure 2(a)). We measured the concentra-
tion of Mg2þ in serum samples from pups after receiv-
ing vehicle or MgSO4 at 3 or 24 h after administration
(Figure 2(b)). For all doses tested, serum Mg2þ levels
increased transiently, peaking at 3 h after administra-
tion and returning to baseline within 24 h.
Administration of the neuroprotective dose of MgSO4
(1.1mg/g) resulted in a peak Mg2þconcentration of
3.3 0.2 mmol/L at 3 h later which is within the thera-
peutic window (2–4 mmol/L) when MgSO4 is given
antenatally to women for seizure prophylaxis in pree-
clampsia or for neuroprotection. As pre-exposure with
MgSO4 protects the brain in spite of the levels of mag-
nesium being within the physiological range during/
after HI, these data support our hypothesis that
MgSO4 induces CNS tolerance (i.e. confers precondi-
tioning) rather than conferring direct protection
during/after the insult.
Preconditioning with MgSO4 does not change CBF
We then explored the possible mechanisms behind the
profound preconditioning eﬀect of MgSO4. It is well-
known that MgSO4 has cerebrovascular eﬀects,
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modulating the release of calcitonin gene-related pep-
tide and nitric oxide,39 and could theoretically improve
CBF during HI, explaining its protective action.
However, no signiﬁcant diﬀerence in CBF could be
detected between MgSO4 and vehicle at 24 h after
administration or during the subsequent period of HI
(Figure 2(c)), implying that MgSO4 does not provide
protection by aﬀecting CBF.
MgSO4 regulates mitochondrial/metabolic mRNA
and miRNA in the brain
The development of CNS injury resistance required
>12 h delay after MgSO4 injection (Figure 1).
Previous studies have shown that preconditioning pro-
tection can depend on gene transcription and protein
translation,16 therefore we analyzed the eﬀect of
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Figure 1. Evaluation of MgSO4 preconditioning protection.(a) Macroscopic brain injury assessment – brains were collected from rat
pups preconditioned with (a) vehicle (n¼ 18) or (b) MgSO4 (n¼ 17) 24 h prior to HI, collected seven days post HI (p< 0.0001). Brain
injury analyses were performed on MAP-2 stained sections (c and d) and MBP-stained sections (e and f) at the level of anterior
hippocampus from brains shown in image (a) and (b). (B) Overall summary of macroscopic brain injury score at 6 days–12 h; n¼ 72/
condition (p< 0.0001) (Mann–Whitney U test, Mean SEM). (c) Macroscopic brain injury score and measurement of grey (MAP-2)
and white (MBP) matter injury at PND 14 after i.p. injection with NaCl (vehicle) or MgSO4 at different time points prior to and post
HI, (p< 0.05) (Mann–Whitney U test, Mean SEM).
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MgSO4 on mRNA and miRNA expression in the cere-
bral cortex. Firstly, gene expression in MgSO4 and
vehicle-treated groups was analyzed by microarray
and compared with ANOVA (p< 0.05) alone or
combined with the requirement of 1.3 fold
change. Multiple genes and miRNAs were altered
(Figure 3(a)) and several of them have been found to
be regulated in other preconditioning paradigms
(Tables S3 and S4). Selective RT-PCR was performed
to conﬁrm diﬀerences observed by microarray, estab-
lishing that MgSO4 indeed modulates gene expression
(Figure 3(b)).
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Figure 2. MgSO4 dose-response, serum concentrations and effect on cerebral blood flow.(a) Preconditioning protection induced by
different doses of MgSO4; 0.37mg/g (vehicle n¼ 20, MgSO4 n¼ 20), 0.55mg/g (vehicle n¼ 18, MgSO4 n¼ 28) or 1.1mg/g (vehicle
n¼ 18, MgSO4 n¼ 16) (p< 0.0001), unpaired t-test Mean SEM. (b) Concentration of Mg2þ in serum samples collected at 3 h or 24 h
after injection with one of the three doses of MgSO4 (0.37mg/g (n¼ 14), 0.55mg/g (n¼ 13), or 1.1mg/g (n¼ 17) or an equivalent
volume of vehicle (n¼ 18) (p< 0.0001), unpaired t-test Mean SEM. (c) Cerebral blood flow (CBF) was measured in ipsi- and
contralateral hemispheres 24 h after MgSO4 or vehicle administration in a group not subjected to HI, (no HI; vehicle n¼ 11, MgSO4
n¼ 9) and in groups exposed to 30min (vehicle n¼ 7, MgSO4 n¼ 8) and 60min (vehicle n¼ 9, MgSO4 n¼ 8)of HI. There were no
significant differences in CBF between MgSO4 treated and vehicle groups (p> 0.05).
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Figure 3. MgSO4 PC causes regulatory changes in mRNA and miRNA and downregulation of metabolic and mitochondrial pathways.
(a) Summary of mRNA and miRNA findings at 3 h and 24 h after administration of MgSO4 or vehicle, ANOVA p< 0.05 with and
without fold change > 1.3. (b) RT-PCR results for a selection of genes upregulated at 3 h post injection with MgSO4 or vehicle;
FKBP51 (from 0.52 0.04 DCq; n¼ 6 to 0.85 0.07 DCq; n¼ 6) (p¼ 0.0004); Mt2A (from 0.29 0.03 DCq; n¼ 6 to 0.52 0.06;
n¼ 6) (p¼ 0.02); HIF3a (from 0.26 0.03 DCq; n¼ 6 to 0.86 0.09 DCq; n¼ 6) (p< 0.0001); Osmr (from 0.52 0.04 DCq; n¼ 6 to
0.85 0.07 DCq; n¼ 6) (p¼ 0.0003) (ANOVA, p< 0.05). (c) Principal component analysis plot of all regulated genes 24 h after MgSO4/
vehicle injection (n¼ 6/group). (d) Network analysis demonstrates that several genes for enzymes in the citric acid cycle were
downregulated (marked in green) after MgSO4 injection, including succinate dehydrogenase, malate dehydrogenase, isocitrate
dehydrogenase and 2-ketoglutarate complex at 24 h. (e) Heatmap cluster of all genes from (a). (f–g) Heatmaps visualizing the genes
regulated in metabolic (f) and mitochondrial (g) pathways at 24 h post MgSO4 vs. vehicle, respectively.
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Using ClustVis, a PCA plot40 was constructed using
data from all 907 regulated genes at 24 h (Figure 3(c))
showing a clear separation between samples from
MgSO4 pre-treated animals and vehicle oﬀering further
evidence that MgSO4 aﬀects gene transcription in the
brain. Many of the regulated genes relate to mitochon-
drial function and at 24 h after MgSO4 administration,
both succinate dehydrogenase (SDH) and malate
dehydrogenase were signiﬁcantly downregulated
(Figure 3(d)). Furthermore, pathway analysis demon-
strated that metabolic pathways were signiﬁcantly
downregulated at 24 h after MgSO4 vs. vehicle
(Z score: 2.98) which was further conﬁrmed in the
gene ontology analysis where 226/351 cellular meta-
bolic process genes (Z score: 4.14) and 72/95 mitochon-
drial genes (Z score: 4.14) were downregulated
(GeneSifter software, Geospiza). The gene data used
for the PCA (above; 3(c)) was then used to create a
heatmap showing up- or downregulation of multiple
genes at 24 h after MgSO4 treatment compared to vehi-
cle (Figure 3(e)). Heatmap clusters were constructed
from all genes found to be regulated in metabolic
pathways visualizing that 65% of genes in cellular
metabolic processes (Figure 3(f)) and 76% of mito-
chondria-related genes were downregulated (Figure
3(g)). We also performed analyses of corresponding
proteins utilizing an experimental dataset from the
proteomic study of about 7300 mitochondrial proteins
from MitProNet40,41 (a functional linkage network of
mitochondrial proteins generated by integrating gen-
omic features encoded by a wide range of datasets
including genomic context, gene expression proﬁles,
protein-protein interactions, functional similarity and
metabolic pathways). We superimposed our microarray
data on MitoProtNet dataset and performed IPA ana-
lyses and found a signiﬁcant down-regulation of genes
corresponding to proteins in complexes I, II, III and IV
of the ETC at 24 h by MgSO4 (ANOVA; p< 0.05).
MgSO4 targets pathological succinate accumulation
in the immature brain
These results indicate that MgSO4 modulates mito-
chondrial pathways, including succinate metabolism,
which is interesting but not surprising as magnesium
is involved in regulation of >600 enzymatic reactions
including those involved in energy metabolism.39,42
However, recently Chouchani et al.43 demonstrated
that the extent of succinate increase during ischemia
is critical as it triggers production of ROS and impairs
mitochondrial function. Other groups42 suggest that
succinate triggers a pro-inﬂammatory response which
could be critical during post-HI recovery. Therefore,
we explored whether MgSO4 modulates the metabolo-
mic response before and during HI (Figure S2). The
analysis revealed that the MgSO4-treated samples
diﬀer from vehicle in the 3 h group for cortex
(Figure 4(a)), indicating that MgSO4 itself has an
eﬀect on brain metabolism. Furthermore, MgSO4 sup-
pressed metabolic responses exacerbated in cerebral
cortex during the HI insult. Succinate was signiﬁcantly
increased after HI in the vehicle-treated rats (n¼ 9)
(from 4.1 0.5 a.u. to 11.6 2.4 a.u.; p< 0.01), whereas
no such increase was detected following MgSO4 pre-
treatment (n¼ 6) (from 4.2 0.5 a.u. to 6.6 2.0 a.u.;
NS) (Figure 4(b) and (c)). An increase in GABA in the
cerebral cortex was detected in the vehicle-treated
group (n¼ 9) after 60min of HI (from 2.3 0.2 a.u.
to 4.3 a.u.; p< 0.0001) whereas no increase was
detected in the MgSO4 group (n¼ 6) (from 2.5 0.3
a.u. to 2.5 0.4 a.u.; NS). As expected, phosphocrea-
tine and ATP/ADP levels decreased signiﬁcantly in the
vehicle group after HI (p< 0.0004 and p< 0.0001,
respectively), whereas the levels were better maintained
in the MgSO4 group. Additionally, a signiﬁcant diﬀer-
ence in phosphocreatine (p< 0.03) and ATP/ADP
(p< 0.03) concentration was detected between the vehi-
cle and MgSO4 pre-treated groups. Lactate was signiﬁ-
cantly increased in both the MgSO4 (from 6.5 0.6 a.u.
to 30.2 5.7 a.u.; p< 0.0001) (n¼ 6) and vehicle group
(from 6.1 0.6 a.u. to 48.8 8.0 a.u.; p< 0.0001)
(n¼ 9) although with a tendency towards being higher
in the latter (NS). Glucose concentrations were
lower after HI with no diﬀerence between groups
(Figure 4(c)). These metabolic data indicate that the
potentially toxic succinate accumulation is attenuated
by MgSO4 pre-treatment and this eﬀect was paralleled
by preservation of high-energy phosphates indicating
protection of mitochondrial function.
MgSO4 preserves brain mitochondrial
respiratory capacity
The Complex-I-mediated respiratory capacity of iso-
lated brain mitochondria was analyzed using high-reso-
lution respirometry (O2k chamber). No signiﬁcant
diﬀerence in RCR, i.e. STATE 3/STATE 4 respiration,
was detected between MgSO4 and vehicle at 24 h after
injection (Figure 5(a) and (c)). We found, however, that
the RCR decreased from 5.3 0.5 pmol/(s*mg); n¼ 7
to 2.7 0.4 pmol/(s*mg); n¼ 6; p< 0.002 after 30min
HI in the vehicle group, whereas it remained unchanged
at 30min HI in the MgSO4 group (4.5 0.2 pmol/
(s*mg); n¼ 6 before HI and 4.4 0.6 pmol/(s*mg)
after 30min HI; n¼ 7) (Figure 5(b) and (c)). Hence,
the RCR was signiﬁcantly higher in the MgSO4 group
compared with vehicle at 30min HI induced 24 h after
administration (p< 0.05).
To further characterize the eﬀect of MgSO4 on mito-
chondrial function, we studied Complex-II-mediated
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mitochondrial respiration using succinate and rotenone
in the O2k. The results showed a signiﬁcant increase in
succinate-driven OXPHOS (S-OXPHOS) in the MgSO4
pre-treated group compared to vehicle (p< 0.005)
(Figure 5(e) and (f)) after 60min HI. Further we ana-
lyzed the succinate driven ETS capacity (S-ETS) using
the uncoupler FCCP to induce maximal Complex-
II-mediated respiration, which was signiﬁcantly higher
in the MgSO4 group (p< 0.005) (Figure 5(e) and (f)).
No signiﬁcant increase could be detected in the
Complex-II-mediated respiratory capacity after the
addition of FCCP during these settings (compared
to S-OXPHOS) which is in concordance with previ-
ous reports.44 A signiﬁcant diﬀerence was also detected
in the basal mitochondrial respiration (STATE 1)
between the MgSO4 pre-treated group and vehicle
(p< 0.009) as well as in STATE 2 respiration,
(when ADP is added to mitochondria in the absence
of reducing substrates) (p< 0.005, n¼ 6/group)
(Figure 5(d)). In summary, these data indicate that
MgSO4 preserves mitochondrial Complex-I and-II res-
piration after HI.
Figure 4. MgSO4 preconditioning prevents succinate and GABA accumulation as well as high-energy phosphate depletion in the
brain after HI.(a) Principal component analysis (OPLS-DA) of the metabolomic analysis of cortex samples (ipsi- and contralateral)
collected 3 h after i.p. injection with vehicle (n¼ 9) as shown in blue or MgSO4 (n¼ 6) shown in green. (b) Metabolic trace plots of
succinate levels in cerebral cortex after 60min of HI (red) in samples from rats injected with vehicle (n¼ 9) or MgSO4 (n¼ 6) 24 h
prior to HI in contra- and ipsilateral hemisphere and in animals exposed to treatment without HI 3 h or 24 h prior to sampling.
(c) Cerebro-cortical metabolites 3 h and 24 h after administration of MgSO4 or vehicle, and 24 h of MgSO4 or vehicleþ 60min of HI
(600). There was an accumulation of succinate (p< 0.05) and GABA (p< 0.001) after 60min of HI in the vehicle group but not in
MgSO4-treated group. Depletion of phosphocreatine (p< 0.0002) and ADP/ATP (p< 0.02) was attenuated during HI in the MgSO4
group compared to vehicle-treated group. The lactate concentration increased to the same extent in MgSO4 pre-treated animals
(p< 0.0001) as in vehicle (p< 0.0001) after HI and glucose concentrations decreased in the cerebral cortex following HI in both
groups (n¼ 6–10/condition), (one-way ANOVA with Tukey’s multiple comparisons test).
10 Journal of Cerebral Blood Flow & Metabolism
Figure 5. MgSO4 preconditioning preserved brain mitochondrial respiration after HI.(a) Respirogram showing vehicle (black) and
MgSO4-(blue) treated samples analyzed 24 h post injection. (b) Respirogram showing vehicle (black) and MgSO4-(blue) treated samples
analyzed after 30min of HI. Respiration was significantly higher in the MgSO4-treated group compared to vehicle (p< 0.05) (Unpaired
t-test, Mean SEM) (n¼ 6–7/group). (c) Mitochondrial respiration. A significantly higher RCR was found in brain mitochondria
isolated from animals pretreated with MgSO4 compared to vehicle-treated animals after 30min of HI (30
0HI). No difference could be
detected in RCR between MgSO4-treated animals with or without HI, whereas there was a 50% drop in RCR in response to HI in
the vehicle-treated group (p< 0.002), (ANOVA, p< 0.05). (d) Basal mitochondrial respiration (STATE 1) as well as respiration in the
presence of added ADP but absence of reducing substrates (STATE 2) in vehicle (black) vs. MgSO4 (blue; n¼ 4/group) (p< 0.03). (e)
Complex-II-mediated respiration driven by succinate as reducing substrate during blockage of Complex-I by Rotenone in MgSO4 vs.
vehicle (p< 0.03). Also, maximal ETS capacity induced by addition of FCCP (p< 0.03) (n¼ 5/group), (Mann–Whitney U test,
Mean SEM). (f) Respirogram showing the respiratory activity of isolated mitochondria from MgSO4 (blue) compared to vehicle
(black) group. The time-point for addition of each substrate is indicated by arrows in the figure.
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MgSO4 attenuates ROS production in the brain
after HI
Next, we investigated whether this functional
improvement was associated with alleviation of
oxidative stress. Production of ROS in isolated brain
mitochondria was measured using Amplex Red. We
found that the Complex-I-linked production of ROS
tended to decrease in the MgSO4 samples (n¼ 4) at
30min HI compared to vehicle (n¼ 5) in the presence
of NADH generating substrates (pyruvate, glutamate
and malate) (Figure 6(a)) as well as when FCCP had
been added (N-ETS) (Figure 6(b)). Furthermore, the
production of ROS was measured using the O2k in
the absence of exogenous NADH generating substrates
with the purpose of detecting endogenous ROS produc-
tion only. When succinate was added to the isolated
brain mitochondria stimulated with ADP, the detected
production of ROS was 0.004 0.001 pmol/(s*mg);
n¼ 6 in vehicle vs. 0.002 0.001 pmol/(s*mg) (n¼ 6)
in the MgSO4 group. Following the addition of
FCCP, a signiﬁcantly higher production of ROS was
detected in the vehicle group (0.004 0.001 pmol/
(s*mg); n¼ 6) compared with the MgSO4 group
(0.002 0.0001 pmol/(s*mg); n¼ 6) (Figure 6(c))
(p¼ 0.02). We also used IPA to analyze our microarray
data and detected downregulation of several genes
involved in the pathway of ROS production in the
MgSO4 group compared to vehicle, predicting inhib-
ition of generation and formation of ROS
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Figure 6. MgSO4 preconditioning attenuates brain mitochondrial ROS following HI. (a) ROS production at 30min HI in the presence
of the NADH substrates pyruvate, glutamate and malate in MgSO4 and vehicle group (n¼ 4/group). (b) ROS production at 30min HI at
maximal ETS induced by addition of FCCP (n¼ 4/group). (Mann–Whitney U test, Mean SEM; NS). (c) ROS production in MgSO4 vs.
vehicle pre-treated samples collected at 60min HI at the addition of succinate and FCCP (n¼ 6/group) controlled for level of
mitochondrial respiration by dividing the total ROS production (the AMP-flux) by the mitochondrial respiration (O2 flux) (one-way
ANOVA with Tukey’s multiple comparisons test, p< 0.05). (d) IPA prediction of decreased ROS generation and formation in the
MgSO4 group at 24 h after administration. Upregulated genes displayed in red and downregulated genes displayed in green.
Downregulation as predicted by IPA is illustrated in blue.
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(Figure 6(d)) corresponding to our ﬁndings using the
O2k equipment.
MgSO4 pre-treatment attenuates the post HI
accumulation of chemokines and
pro-inflammatory cytokines
Previous studies suggest that succinate activates the
succinate receptor 1 (SUCNR1) leading to activation
of pro-inﬂammatory responses via p38, NFAT (nuclear
factor of activated T-cells) and NFkB (nuclear factor
kappa B) signaling.42 Therefore, we speculated
that MgSO4 could modify the cytokine/chemokine
responses after HI due to the attenuation of succinate
accumulation (above). Furthermore, mitochondrial
ROS production has been suggested to enhance the
pro-inﬂammatory response42 and as MgSO4 reduced
ROS production, we expected that the inﬂammatory
response would be aﬀected. We prepared whole brain
homogenate at 6 and 24 h after HI comparing the
MgSO4 and vehicle groups. Indeed, pre-treatment
with MgSO4 signiﬁcantly attenuated the accumulation
of MCP-1 (CCL2), IL-1 a, IL-1 b, MIP-3a (CCL20),
GRO/KC (CXCL1), MIP-1 a (CCL3), M-CSF and
GM-CSF at 6-24 h after neonatal HI (Figure 7(a) to
(h)), whereas the anti-inﬂammatory cytokines IL-4
and IL-10 were not diﬀerent between the groups
(vehicle no HI; n¼ 3, MgSO4 no HI; n¼ 4, vehicle
HIþ 6 h; n¼ 10, MgSO4 HIþ 6 h; n¼ 11, vehicle
HIþ 24 h; n¼ 10, MgSO4 HIþ 24 h; n¼ 9) (Figure
7(i) to (j)).
Discussion
We have demonstrated for the ﬁrst time that MgSO4
conferred preconditioning to the immature rat brain if
given 6 days–12 h prior to an HI or excitotoxic insult
reducing brain injury in all areas, particularly cerebral
cortex, by as much as 80%. Administration of MgSO4
induced mRNA/miRNA changes in the cerebral cortex
previously shown to be regulated in response to other
forms of preconditioning and many of them related to
mitochondria.45–48 Metabolic pathways were generally
downregulated including mitochondrial network genes,
especially those corresponding to proteins in the elec-
tron transport chain. The metabolome was signiﬁcantly
modulated in both serum and brain at 3 h after MgSO4.
Succinate accumulation, mitochondrial functional
deterioration during HI and the increase of mitochon-
drial ROS production and tissue cytokines/chemokines
after the insult were all attenuated by pre-treatment
with MgSO4.
MgSO4 was given as an intraperitoneal bolus caus-
ing a temporary increase in serum magnesium concen-
tration to 3.3 mmol/L at 3 h but it is important to
point out that the levels were completely normalized
at 24 h post injection, i.e. the concentration of magne-
sium was at physiological levels during and after the HI
insult. According to previous studies, increases of
serum MgSO4 elevate magnesium concentrations in
the brain tissue49 as well as in the cerebrospinal
ﬂuid50 suggesting that extracellular and intracellular
magnesium concentrations increase at least transiently
in the brain. Magnesium modulates calcium hemostasis
and the activity of multiple enzymes51 possibly explain-
ing why the metabolome is altered in blood and brain at
3 h after MgSO4 administration. These metabolic/
enzymatic changes may secondarily induce the subtle
gene transcription changes detected in the brain at
3 and 24 h after treatment, probably contributing to
development of mitochondrial and CNS resistance
as well as the metabolism downregulation and attenu-
ation of succinate accumulation in response to HI.
Indeed, the gene ontogeny and pathway analysis
indicating metabolic suppression by MgSO4 are sup-
ported by a recent clinical study demonstrating a
drop in cerebral oxygen consumption and cerebral
oxygen extraction in newborns pre-exposed to MgSO4
antenatally.52 These changes occurred in spite of unaf-
fected CBF52 which agrees with our results showing
that CBF was not diﬀerent between the MgSO4 and
vehicle group at 24 h after administration or even
during the subsequent HI, supporting that both
groups were suﬀering from a similar degree of primary
HI insult.
Succinate is reported to accumulate in tissues,
including the immature and adult brain,53,54 in response
to HI leading to succinate-driven excessive mitochon-
drial production of ROS during reperfusion and subse-
quent aggravation of injury.51 The cause of the
succinate increase is reversal of SDH activity, resulting
in the conversion of fumarate to succinate, driven by
fumarate overﬂow from purine nucleotide breakdown
and partial reversal of the malate/aspartate shuttle.51
The SDH inhibitor dimethyl malonate prevents accu-
mulation of succinate and ROS, conferring signiﬁcant
neuroprotection.53 Presently, we found that MgSO4
pre-treatment prevented the accumulation of succinate
and improved mitochondrial function in the neonatal
brain. Interestingly, the mRNA analysis of the rat brain
tissue demonstrated that the genes for SDH and malate
dehydrogenase were downregulated by MgSO4. When
analyzing Complex-II-mediated succinate-driven res-
piration in isolated mitochondria, we detected an
increase in the MgSO4 pre-treated group, whereas no
such increase was detected in the vehicle group, further
conﬁrming our data on endogenous succinate accumu-
lation in the vehicle group. GABA accumulation during
HI was also attenuated by MgSO4. Speculatively, mag-
nesium modulates both the reversal of SDH and the
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GABA-shunt, thereby preventing accumulation of
toxic levels of succinate in the brain tissue after HI.
Succinate accumulation during HI can also trigger
a more profound inﬂammation42,55 during the
secondary phase after HI which may worsen brain
injury.1 In fact, several studies show that MgSO4
attenuates the pro-inﬂammatory reaction in experimen-
tal models.56,57 Additional experiments are needed to
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Figure 7. Attenuation of chemokines and pro-inflammatory cytokine accumulation in the brain by preconditioning with MgSO4.
(a–h) Attenuation of MCP-1, IL-1a, IL-1b, MIP-3a, GRO-KC, MIP-1a, M-SCF and GM-CSF accumulation at 6 h and/or 24 h post HI in
the MgSO4-treated group. No significant difference in IL-10 (I) or IL-4 (J) between the groups at either time-point. (one-way ANOVA
with Tukey’s multiple comparisons test, p< 0.05) (vehicle no HI; n¼ 3, MgSO4 no HI; n¼ 4, vehicle HIþ 6 h; n¼ 10, MgSO4 HIþ 6 h;
n¼ 11, vehicle HIþ 24 h; n¼ 10, MgSO4 HIþ 24 h; n¼ 9) .
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clarify the mechanisms behind succinate accumulation
in the immature brain and to elucidate how these meta-
bolic events and mitochondrial functions are modu-
lated by magnesium preconditioning as well as their
speciﬁc role in neuroprotection.
Many enzymes in intermediary metabolism are
modulated by magnesium, aﬀecting >600 bio-
logical reactions51 which could hypothetically shift
the balance and attenuate succinate accumulation.
Indeed, we found that genes related to proteins in
the ETC were downregulated by MgSO4 which has
been shown to occur also in preconditioning of the
heart in parallel to improvement of mitochondrial
respiratory recovery.48 Recently, it was discovered
that when preventing degradation of components of
the ETC, such as SDH, BAX dependent apoptotic
cell death known to be critical in HI brain injury,58
was attenuated.59
This study oﬀers mechanistic information indicating
that succinate metabolism and mitochondrial function
are involved in preconditioning by MgSO4. However,
more detailed information (using 1H-NMR, 31P-NMR
and 13C-NMR) on how the metabolic network is modu-
lated by MgSO4 treatment is needed, having to be
addressed in the future.
Concerning clinical implications, the present ﬁnd-
ing that a transient increase of serum MgSO4 induces
tolerance in the developing brain rather than provid-
ing a direct neuroprotective eﬀect during/after the
insult is of great importance. Indeed, these data sup-
port the clinical ﬁndings that MgSO4 is an eﬀective
neuroprophylaxis if treatment starts antenatally,
some-time before the critical period for brain insults
during delivery and the ﬁrst few days of life.
However, our results also indicate that it may be
suﬃcient to oﬀer a MgSO4 bolus (high enough to
reach a transient magnesium increase to >2.5mmol/
l which in most patients would correspond to 6 g of
MgSO4) rather than administration of MgSO4 infu-
sions during delivery up until birth. Today there is no
consensus as to required MgSO4 dose/duration for
neuroprophylaxis as all published randomized trials
have followed diﬀerent dosing regimens.10–13 Some
studies even indicate that long-lasting
infusions of MgSO4 may increase necrotizing colitis,
gut perforations and perinatal mortality,60–62 prob-
lems that could be avoided by administration of
only a bolus. In addition, MgSO4 infusions require
much more extensive monitoring of the mother than
if only a bolus dose is provided which aﬀects com-
pliance for clinical implementation. Therefore, clinical
studies are warranted to investigate whether provid-
ing only a bolus of MgSO4 is an eﬃcient mode of
neuroprophylaxis with superior safety and compliance
in women in preterm labor.
Furthermore, the understanding that MgSO4
induced preconditioning protection of the immature
CNS could lead to development of prophylactic treat-
ment of other patients at high risk such as cases with
high risk of intrapartum asphyxia or cases undergoing
open heart surgery.
In conclusion, MgSO4 induces strong precondition-
ing of the immature brain which provides resistance to
HI- and excitotoxicity-mediated injury in rats and mice.
Magnesium increases in the CNS and have previously
been shown to modulate enzymatic activities, calcium
homeostasis and NMDA receptor activity. These alter-
ations are anticipated to provoke transcriptomal
changes with modulation of neuroprotective and meta-
bolic mRNAs and miRNAs. The metabolism will be
downregulated and altered leading to reduced succinate
toxicity, mitochondrial protection and slower loss of
high energy phosphate reserves in the brain tissue
after HI. Speculatively, these reactions contribute
to attenuated ROS production and inﬂammation
(Figure S3).
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